Gabelli Funds’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Gabelli Funds’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-62,238	Closed	-$629K	–	1230
2022 Q4	$629K	Sell	62,238 -11,065	-15%	-$111K	﹤0.01%	895
2022 Q3	$726K	Hold	73,303	–	–	0.01%	896
2022 Q2	$718K	Hold	73,303	–	–	0.01%	932
2022 Q1	$714K	Hold	73,303	–	–	﹤0.01%	976
2021 Q4	$710K	Hold	73,303	–	–	﹤0.01%	997
2021 Q3	$711K	Buy	+73,303	New	+$709K	﹤0.01%	983

Gabelli Funds's EBAC Position: Q1 2023 in Review

Gabelli Funds sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 62,238 shares — an estimated $629K sold.

Gabelli Funds first reported a position in EBAC in Q3 2021 and held it in 6 quarters. The position peaked at $726K in Q3 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Gabelli Funds reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Gabelli Funds sold 62,238 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $629K.
Gabelli Funds first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q3 2021 and held it in 6 quarters.
Gabelli Funds's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $726K in Q3 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Gabelli Funds's 13F filing for Q1 2023, filed 12 May 2023.